Compare GAME & NNVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GAME | NNVC |
|---|---|---|
| Founded | 2011 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.4M | 35.2M |
| IPO Year | 2024 | 2008 |
| Metric | GAME | NNVC |
|---|---|---|
| Price | $3.31 | $1.42 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 372.5K | ★ 392.1K |
| Earning Date | 04-08-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 65.14 | 10.00 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $44,999,302.00 | N/A |
| Revenue This Year | $87.12 | N/A |
| Revenue Next Year | $21.14 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.24 | $0.85 |
| 52 Week High | $3.85 | $2.23 |
| Indicator | GAME | NNVC |
|---|---|---|
| Relative Strength Index (RSI) | 66.97 | 66.85 |
| Support Level | $0.33 | $1.45 |
| Resistance Level | $3.85 | $1.47 |
| Average True Range (ATR) | 0.28 | 0.09 |
| MACD | -0.07 | 0.04 |
| Stochastic Oscillator | 53.10 | 96.71 |
GameSquare Holdings Inc is a vertically integrated digital media, entertainment, and technology company focused on gaming and youth culture audiences. The company operates through four reportable segments: Owned and Operated IP, Agency, SaaS and managed services, and Yield. It provides services including influencer marketing, esports talent management, creative production, merchandise and consumer products, live streaming analytics, and digital media solutions through its various brands and platforms. It generates the majority of its revenue from the Agency segment.
Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.